Close
CDMO Safety Testing 2026
Novotech

Glenmark settles patent case with Daiichi, Genzyme

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.
- Advertisement -

Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA).

With this settlement, Glenmark can roll out its generic Colesevelam Hydrochloride products on 02 April 2015 or earlier under certain circumstances.

At present Daiichi Sankyo markets the drug in powder and tablet forms to treat primary hyperlipidemia and type 2 diabetes mellitus.

Late last year, Daiichi Sankyo and Genzyme filed a patent infringement case in the US District Court for the District of Delaware to stop the India-based pharma firm from selling its ANDA prior to expiration.

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Quantum Machine Learning in Pharma Research Growth

The convergence of artificial intelligence and quantum processing is opening new avenues for rapid discovery and innovation within the life sciences. By utilizing advanced mathematical models that operate across multi-dimensional datasets, researchers can now identify complex biological patterns and predict molecular behaviors with a speed that surpasses traditional computational methods. This transformation is accelerating the development of novel therapies and providing deeper insights into disease mechanisms, fundamentally altering the trajectory of pharmaceutical research and development.

Quantum Sensors Enabling Advanced Drug Diagnostics

The landscape of medical diagnostics is being reshaped by the introduction of sensing technologies that operate with atomic-level sensitivity. By providing high-fidelity measurements and real-time data, these tools allow for the detection of subtle biological changes and chemical markers that were previously invisible to conventional equipment. This advancement is enhancing the precision of drug testing and clinical monitoring, leading to earlier disease detection and more effective therapeutic interventions across the global healthcare spectrum.

Quantum Computing Optimizing Pharma Supply Chains

The global distribution of pharmaceutical products is facing unprecedented challenges that demand a new level of logistical precision and resilience. By utilizing advanced analytical models, companies can now navigate complex international networks with greater efficiency, ensuring that temperature-sensitive medicines and life-saving therapies reach their destinations without delay. This evolution toward a more intelligent and responsive supply chain is critical for maintaining public health and responding effectively to emerging medical needs on a global scale.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »